tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright
PremiumThe FlyPlus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright
25d ago
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
Premium
Company Announcements
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
26d ago
Plus Therapeutics announces anticipated milestones for FY26
Premium
The Fly
Plus Therapeutics announces anticipated milestones for FY26
26d ago
Buy Rating for Plus Therapeutics: Strategic Advancements and Promising Developments in CNSide Diagnostics and LM Program
PremiumRatingsBuy Rating for Plus Therapeutics: Strategic Advancements and Promising Developments in CNSide Diagnostics and LM Program
2M ago
Plus Therapeutics expands CNSide assay platform to State of California
Premium
The Fly
Plus Therapeutics expands CNSide assay platform to State of California
2M ago
Plus Therapeutics announces expansion of CNSide Team
Premium
The Fly
Plus Therapeutics announces expansion of CNSide Team
2M ago
Plus Therapeutics’ assay secures national coverage agreement with Humana
PremiumThe FlyPlus Therapeutics’ assay secures national coverage agreement with Humana
3M ago
Plus Therapeutics Gains Nasdaq Extension for Compliance
Premium
Company Announcements
Plus Therapeutics Gains Nasdaq Extension for Compliance
3M ago
Plus receives additional extension to regain compliance with Nasdasq
Premium
The Fly
Plus receives additional extension to regain compliance with Nasdasq
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100